Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Alison Moore, the most common co-covered peer. The tracked stories average 9 original sources each. NXT 41 appears in 1 tracked Cross-Sector story from March 12, 2026.
1 verified story tracked
Last mentioned: Mar 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Alison Moore, the most common co-covered peer. The tracked stories average 9 original sources each. NXT 41 appears in 1 tracked Cross-Sector story from March 12, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NXT 41. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
